{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:55Z","timestamp":1784196475674,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:20:19Z","timestamp":1776727219000},"page":"649-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-2064","authenticated-orcid":false,"given":"Maxim John","family":"Levy Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena","family":"Siqueira Tavares de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza","family":"de Medeiros Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aed.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2003.257","article-title":"Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations","volume":"48","author":"Ai","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.aed.2026.04.001_bib2","first-page":"438","article-title":"Dermopathy of Graves\u2019 disease (pretibial myxedema): long-term outcome","volume":"87","author":"Schwartz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.04.001_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2652174","article-title":"Morphological diversity of pretibial myxedema and its mechanism of evolving process and outcome: a retrospective study of 216 cases","volume":"2016","author":"Lan","year":"2016","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.aed.2026.04.001_bib4","first-page":"1065","article-title":"Graves dermopathy associating toes lesions, pretibial myxedema and acropachy, rare, but aggressive extrathyroidal manifestation of Graves\u2019 disease","volume":"63","author":"Marinescu","year":"2016","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.aed.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1067\/mjd.2003.323","article-title":"Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves\u2019 disease","volume":"48","author":"Anderson","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.aed.2026.04.001_bib6","first-page":"2084","article-title":"Thyroid eye disease","volume":"12","author":"Rashad","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.aed.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.radcr.2019.04.021","article-title":"Thyroid acropachy: a rare skeletal manifestation of autoimmune thyroid disease","volume":"14","author":"Jadidi","year":"2019","journal-title":"Radiol Case Repo"},{"key":"10.1016\/j.aed.2026.04.001_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.8478","article-title":"Pretibial myxedema in Graves\u2019 disease: a case report and treatment review of the literature","volume":"12","author":"Nguyen","year":"2024","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aed.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aed.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-024-04462-x","article-title":"Graves\u2019 disease thyroid dermopathy: a case report","volume":"18","author":"Tashkandi","year":"2024","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib12","first-page":"YD01","article-title":"Pretibial myxedema associated with euthyroid hashimoto\u2019s thyroiditis: a case report","volume":"8","author":"Nair","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.aed.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdcr.2021.04.018","article-title":"An atypical presentation of pretibial myxedema in a euthyroid patient with absent antithyroid autoantibodies","volume":"12","author":"Beaulieu","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00128071-200506050-00003","article-title":"Pretibial myxedema: pathophysiology and treatment options","volume":"6","author":"Fatourechi","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.aed.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2169\/internalmedicine.49.2617","article-title":"Treatment of pretibial myxedema (PTM) with topical steroid ointment application with sealing cover (steroid occlusive dressing technique: steroid ODT) in Graves' patients","volume":"49","author":"Takasu","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.aed.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdrv.2025.03.008","article-title":"Update on pathophysiology and treatment of pretibial myxedema: a comprehensive review of the literature","volume":"4","author":"Katsiaunis","year":"2025","journal-title":"JAAD Rev"},{"key":"10.1016\/j.aed.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/DAD.0000000000002597","article-title":"Upregulation of insulin-like growth Factor-1 receptor expression in pretibial myxedema: evidence for a treatment target","volume":"46","author":"Walsh","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.aed.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.14740\/jocmr4352","article-title":"Thyroid-stimulating hormone receptor autoimmunity and local factors in multiple risk factors are mainly involved in the occurrence of pretibial myxedema","volume":"12","author":"Lan","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.aed.2026.04.001_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202530","article-title":"Nodular pretibial myxoedema after treatment of Graves disease with radioactive iodine ablation therapy","volume":"2014","author":"Ponnusamy","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/jpm14101027","article-title":"Teprotumumab for the treatment of thyroid eye disease: why should we keep our eyes \u201cwide open\u201d? \u2013 a clinical and pharmacovigilance point of view","volume":"14","author":"Martel","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.aed.2026.04.001_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","article-title":"Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy","volume":"29","author":"Slentz","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.aed.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","article-title":"Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth Factor-1 receptor-blocking antibody, in thyroid eye disease","volume":"60","author":"Xin","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.aed.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.aed.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aed.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jdcr.2020.09.003","article-title":"Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease","volume":"6","author":"Varma","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdcr.2021.08.026","article-title":"A case of pretibial myxedema treated with teprotumumab","volume":"16","author":"Petit","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6621","article-title":"Graves\u2019 disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab","volume":"10","author":"Bowens","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.06.706","article-title":"34839 game-changer or flop: Teprotumumab may not provide lasting improvement of pretibial myxedema","volume":"87","author":"Emge","year":"2022","journal-title":"JAAD"},{"key":"10.1016\/j.aed.2026.04.001_bib29","first-page":"21","article-title":"Thyroid dermopathy responds to teprotumumab therapy","volume":"2022","author":"Crespo-Trevino","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.36849\/JDD.6854","article-title":"Improvement of pretibial myxedema following administration of teprotumumab","volume":"21","author":"Washington","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.aed.2026.04.001_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjd.21700","article-title":"Teprotumumab as a novel treatment for pretibial myxedema","volume":"187","author":"Mervis","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.aed.2026.04.001_bib32","article-title":"Teprotumumab for treatment of pretibial myxedema","volume":"1","author":"Reyes","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib33","doi-asserted-by":"crossref","DOI":"10.5070\/D329160211","article-title":"Novel teprotumumab treatment of severe thyroid dermopathy; ototoxicity as an adverse side effect","volume":"29","author":"Patel","year":"2023","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.aed.2026.04.001_bib34","article-title":"Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion","volume":"34","author":"Kelly","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2024-260129","article-title":"Thyroid dermopathy and thyroid eye disease associated with hypofunctional autoimmune thyroid disease with high TSI\/anti-TSHR antibodies improved with teprotumumab","volume":"17","author":"Niedzialkowska","year":"2024","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib36","article-title":"Extending the graves\u2019 triad: thyroid eye disease, dermopathy, and acropachy: a clinical response to teprotumumab","volume":"3","author":"Lira","year":"2025","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.aed.2026.04.001_bib37","article-title":"Resolution of thyroid acropachy in a patient treated with teprotumumab: a case report and review of mechanisms","volume":"2025","author":"Chatterjee","year":"2025","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.aed.2026.04.001_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/10507256251414948","article-title":"Beyond the eyes: is teprotumumab effective for thyroid dermopathy?","author":"Hamadi","year":"2026","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.aed.2026.04.001_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/thy.1997.7.3","article-title":"TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema","volume":"7","author":"Stadlmayr","year":"1997","journal-title":"Thyroid"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:37:00Z","timestamp":1784194620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000743"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.04.001","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}